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Summary
To discover mechanisms that mediate plasticity in mammary cells, we characterized signaling 
networks that are present in the mammary stem cells responsible for fetal and adult mammary 
development. These analyses identified a signaling axis between FGF signaling and the 
transcription factor Sox10. Here we show that Sox10 is specifically expressed in mammary cells 
exhibiting the highest levels of stem/progenitor activity. This includes fetal and adult mammary 
cells in vivo and mammary organoids in vitro. Sox10 is functionally relevant, as its deletion 
reduces stem/progenitor competence, while its overexpression increases stem/progenitor activity. 
Intriguingly, we also show that Sox10 overexpression causes mammary cells to undergo a 
mesenchymal transition. Consistent with these findings, Sox10 is preferentially expressed in stem- 
and mesenchymal-like breast cancers. These results demonstrate a signaling mechanism through 
which stem and mesenchymal states are acquired in mammary cells, and suggest therapeutic 
avenues in breast cancers for which targeted therapies are currently unavailable.
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Introduction
The capacity to reprogram differentiated cells in and ex vivo indicates that the differentiated 
state is not as fixed as once thought (Takahashi and Yamanaka, 2006; Tata et al., 2013). 
This plasticity has important implications for cancer, where the dysregulation of stem and 
mesenchymal states appears to be critical in disease initiation and progression. Phenotypic 
lability may endow some types of cancer cells, often termed “cancer stem cells” (CSC), with 
a greater capacity to propagate the disease when assayed in a transplant setting (Al-Hajj et 
al., 2003; Bonnet and Dick, 1997). In contrast to CSCs, which typically exhibit 
mesenchymal characteristics, transcriptome analyses have revealed another class of 
tumorigenic cancer cells whose gene expression profiles resemble those of cells with known 
stem or progenitor cell functions. Tumors with these distinct “stem-like” cancer cells tend to 
appear less differentiated and behave more aggressively, while eliminating such cells can 
attenuate tumor progression (Chen et al., 2012; Eppert et al., 2011; Merlos-Suarez et al., 
2011; Schepers et al., 2012). Stem-like cancer cells may arise either by cell of origin, in 
which the tumor originates in a stem/progenitor cell and retains those properties through 
tumorigenesis, or through reprogramming of differentiated cells into a stem-like state 
(Barker et al., 2009; Schwitalla et al., 2013). Because a significant fraction of triple-negative 
breast cancers contain stem-like cancer cells, we have focused on elucidating the molecular 
mechanisms that specify the mammary stem cell (MaSC) state, assuming that such 
knowledge will deepen our understanding of how such breast cancers initiate and progress.
The mammary gland contains at least two populations of cells with stem or progenitor 
qualities (Shackleton et al., 2006; Stingl et al., 2006). Luminal progenitors comprise a 
heterogeneous population of cells in the luminal fraction of the gland that possess 
clonogenic properties in vitro (Shehata et al., 2012). This population may contain the cell-
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of-origin for stem-like basal-like breast cancers (Lim et al., 2009). Transplantation studies 
also demonstrate that the basal fraction of the gland contains cells capable of generating an 
entire mammary gland. These MaSCs are inferred to possess extensive proliferative, 
invasive, and multi-lineage differentiation potential, as a single MaSC can regenerate a 
functional gland (Shackleton et al., 2006).
Several fundamental aspects of MaSC biology remain to be elucidated. There is no 
consensus on the number of MaSCs within the gland, which has hindered analyses of the 
origin of breast tumors (Tomasetti and Vogelstein, 2015). There is also conflicting data 
about the topographical location of MaSCs in the gland, and the developmental timeframe 
during which these cells retain multi-lineage potential (Rios et al., 2014; Van Keymeulen et 
al., 2011). Both of these problems might be resolved by availability of markers enabling 
prospective MaSC identification. The mechanisms by which mammary cells enter and exit 
from the MaSC state also remain to be defined, and resolving this problem may present 
solutions to those concerning MaSC identification. One recent advance on this topic 
involves the demonstration that Sox9 and Slug act together to convert mammary epithelial 
cells into cells with MaSC-like properties (Guo et al., 2012). However, the degree to which 
this mechanism is utilized in the gland is not clear because the distribution and function of 
Sox9 or Sox9/Slug cells in unperturbed in vivo contexts remain to be defined. Moreover, 
mice that are deficient for Slug do form a complete native mammary gland, which suggests 
that Slug is not an essential determinant of the MaSC state (Nassour et al., 2012). Clearly, a 
better understanding of the transcriptional programs and extrinsic signaling mechanisms that 
regulate the MaSC state are required.
To investigate the biology of MaSCs and MaSC-like cells in cancer, our research has 
focused on the stem cells present during fetal mammary development. During mid-late 
embryogenesis, mammary cells are highly proliferative and invasive, and likely experience 
conditions such as hypoxia and growth-oriented metabolism that resemble those 
encountered by tumor cells (Masson and Ratcliffe, 2014). Fetal MaSCs (fMaSCs) may 
therefore most resemble the MaSC-like cancer cells in breast tumors. Indeed, we previously 
showed that fMaSCs exhibit both the organoid forming and mammary repopulating 
properties found in luminal progenitors and adult MaSCs, respectively (Spike et al., 2012). 
Transcriptome profiling of fMaSCs and adult MaSCs revealed that the fMaSC signature 
gene list is uniquely enriched in basal-like breast tumors, indicating the presence of fMaSC-
like cells in such tumors. This shared biology suggests that fetal mammary development and 
fMaSCs can be utilized to identify molecular mechanisms that govern important functions in 
breast cancer.
Here we describe how analysis of fMaSCs revealed an important function for Sox10 in 
mammary cells. Sox family transcription factors have well defined roles in regulating cell 
fate decisions in different tissues, and at different stages of development (Sarkar and 
Hochedlinger, 2013). Sox factors generally induce preferential differentiation down one cell 
lineage path over another, often by antagonizing the activity of other lineage-specifying 
factors. This phenomenon has best been described with Sox2, and the elucidation of roles 
for Sox2 in multiple different cell fate decisions, each of which occurs in concert with other 
transcription factors (Sarkar and Hochedlinger, 2013). However, when Sox expression or 
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activity is balanced or kept at lower levels in the cell by other key factors, differentiation is 
forestalled and stem and progenitor functions arise (Kopp et al., 2008). This is consistent 
with an emerging model of stem cell specification through the balance of lineage specifiers 
(Loh and Lim, 2011). Sox factors can thus be mediators and markers of both differentiation 
and stemness, depending on expression level and cellular context.
Here, we report that Sox10 plays important regulatory roles in promoting both stem- and 
EMT-like properties in mammary stem cells. Critically, these stem and mesenchymal states 
are acquired independently of one another; this clear distinction prevents potential conflation 
of stem cell and mesenchymal properties, and demonstrates how these distinct states can be 
related by a single factor such as Sox10. We further present evidence that these functions 
may be conserved in certain types of aggressive breast cancers, and demonstrate the 
importance of FGF10 in a paracrine signaling mechanism that regulates Sox10.
Results
Sox10 is an fMaSC- and tumor-associated transcription factor regulated by FGF signaling
To identify molecular mechanisms that specify stem/progenitor cell functions in mammary 
cells, we analyzed transcriptome profiles of fMaSCs and their surrounding fetal stroma 
(fStr) (Spike et al., 2012). We prioritized both transcription factors that are differentially 
expressed in the fMaSC-enriched population and inferred signaling axes between fMaSCs 
and fStr that could regulate their expression. These analyses identified Sox10 as one of the 
most prominent transcription factors associated with the fMaSC population (Fig. 1A). This 
was of immediate interest, as Sox family transcription factors play important roles in 
pluripotent or tissue-specific stem cell states (Sarkar and Hochedlinger, 2013). Further, 
Sox10 in particular has been shown to be a critical transcription factor in reprogramming 
differentiated cells into multipotent stem/progenitor states (Hornig et al., 2013; Kim et al., 
2014; Najm et al., 2013; Yang et al., 2013).
These analyses also revealed high relative expression of FGF7 and FGF10 in the fStr, and 
expression of multiple FGFR family members in the fMaSC population (Fig. 1A). FGF 
signaling plays a critical role in fetal mammary development, and we previously showed 
that fMaSCs could utilize FGF signaling to promote multipotent growth in vitro (Lu et al., 
2008; Mailleux et al., 2002; Spike et al., 2012). Furthermore, FGF signaling has been shown 
to regulate the expression and function of different Sox family transcription factors in 
multiple developing tissues through a feedback loop of unknown mechanism (Chen et al., 
2014; Seymour et al., 2012). These observations led us to hypothesize that an FGF signaling 
axis may regulate Sox10 expression in mammary stem/progenitor cells.
To address this, we grew fMaSCs in 3-D culture conditions in the presence of the pan-FGFR 
inhibitor, JNJ-42756493 (FGFRi). With vehicle-only, fMaSCs form organoids when either 
EGF or bFGF (FGF2) are added to the media, but fail to form organoids if neither growth 
factor is present (Fig. 1B, Supp. Fig. 1). Addition of FGFRi blocked organoid formation if 
FGF is the only available growth factor. However, organoid formation is rescued upon 
adding EGF to media containing FGFRi (Fig. 1B). As the number of dead cells does not 
increase in FGFRi-treated organoids (data not shown), these data demonstrate that fMaSC-
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derived organoids can utilize FGF signaling, and indicate that FGFRi blocks FGF signaling 
without eliciting overt cytotoxicity.
To determine if FGF signaling regulates Sox10 expression in mammary cells, we measured 
Sox10 expression levels in fMaSC-derived organoids plated with vehicle or increasing 
concentrations of FGFRi. Organoid exposure to FGFRi resulted in significant dose-
dependent decreases in Sox10 mRNA expression levels (Fig. 1C). Similarly, by using a 
Sox10-H2BVenus BAC transgenic mouse line (in which H2B-Venus is expressed under 
Sox10 transcriptional regulatory elements) to quantify the Sox10+ cells through Venus 
fluorescence, we found that FGFRi exposure significantly reduced the number of Sox10+ 
mammary organoid cells (Fig. 1D). This effect was observed in a serum-based medium or in 
a serum-free medium (SFM) containing defined growth factors (Fig. 1D, Supp. Fig. 1). 
Organoids that were generated from adult luminal progenitors also showed a reduction in 
Sox10+ cells following FGFRi exposure (Fig. 1D). fMaSCs grown in the presence of SFM 
with EGF + FGF10 developed into organoids with increased numbers of Sox10+ cells 
compared to fMaSCs grown only in SFM with EGF (Fig. 1E). This effect was not seen in 
fMaSCs grown with SFM containing EGF + FGF2, indicating a specific role for FGF10 
signaling through its cognate receptor, FGFR2b. No significant differences in Sox10 levels 
were observed in fMaSCs grown +/− EGF (Supp. Fig 2). These data indicate that FGF 
signaling specifically regulates Sox10 expression levels in mammary cells.
To determine whether elevated Sox10 expression was a feature common to fMaSC and their 
associated human cancer counterparts, we next analyzed the expression of Sox10 across a 
panel of tumor samples representing two distinct breast cancer datasets. This analysis 
revealed that basal-like and claudin-low breast cancers tend to express significantly higher 
levels of Sox10 than the other subtypes of the disease (Fig. 1F), in accordance with two 
recent studies of Sox10 in breast cancer (Cimino-Mathews et al., 2013; Ivanov et al., 2013). 
These two subtypes comprise the bulk of triple negative breast cancers and both are 
frequently metastatic and aggressive. However, they differ in that basal-like breast cancers 
are weakly differentiated and the most fMaSC-like of the breast cancer subtypes, while 
claudin-low breast cancers possess the most EMT-like morphology and transcriptome 
amongst the breast cancer subtypes (Prat et al., 2010; Spike et al., 2012). These findings 
suggest that Sox10 expression may correlate with distinct stem and mesenchymal properties 
in human breast cancers.
Collectively these data identify Sox10 as an FGF responsive, mammary stem cell associated 
transcription factor with likely roles in normal and transformed mammary cells.
Sox10 is a fetal mammary stem cell marker that improves fMaSC purification
To elucidate the role of Sox10 in mammary cells, the Sox10-H2BVenus BAC transgenic 
mouse line was used to visualize Sox10+ cells. Consistent with the fMaSC transcriptome 
data, Sox10 was robustly expressed in all five fetal mammary rudiment pairs (Fig. 2A–C). 
The rudiments at these stages appear to be very primitive, as there is amorphous structure at 
E16, while at E18 the lumen has not yet formed and there is no clear segregation of the 
luminal marker keratin-8 (K8) and the basal marker keratin-14 (K14) (Fig. 2D).
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Sox10+ fetal mammary cells were recovered using flow cytometry for more detailed 
molecular characterization. As cells in the rudiment can be distinguished from surrounding 
stromal cells by the epithelial cell adhesion marker (EpCAM), fetal Sox10+ mammary cells 
were isolated as Sox10+;EpCAM+. Consistent with Fig. 2C, nearly all cells appear to be 
Sox10+ within the rudiment by FACS analysis (Fig. 2E). It is possible that the stability of 
the H2B-Venus fusion protein may yield cells that no longer express Sox10 but still retain 
the Venus fluorescence and thus overrepresent Sox10 expression. To address this, a 
Sox10flox-GFP mouse line in which a less stable GFP reporter is expressed from native Sox10 
transcripts was also analyzed, and confirmed that the majority of fetal mammary cells are 
Sox10+ (Supp. Fig. 3). Consistent with the Sox10-H2BVenus wholemount images, most 
single Sox10flox-GFP cells also co-expressed K8 and K14, suggesting that they may be 
bipotent progenitors or stem cells (Fig. 2F).
Stem/progenitor cell function in these Sox10+ fetal cells was next analyzed using in vitro 
and in vivo stem/progenitor cell assays. Single fMaSCs grown in 3-D culture conditions will 
clonally expand to generate bi-lineage organoids that resemble the architecture of the 
mammary gland with inner K8+ luminal cells and external K14+ basal cells (Spike et al., 
2012). When E18 Sox10+ fetal cells were plated as single cells into 3-D culture conditions, 
they robustly formed bi-lineage organoids (Fig. 2G, 2H, Supp. Fig. 3). This demonstrates 
that the Sox10+ E18 population contains bipotent cells that generate both luminal- and 
basal-like cells. By contrast, the more rare Sox10neg fetal mammary cells formed spheres at 
significantly reduced efficiency. As an in vivo metric of stem cell function, E18 Sox10+ 
fetal cells were also transplanted into cleared fat pads of immune-compromised mice. As 
few as five Sox10+ fetal cells were sufficient to generate a full mammary gland, further 
indicating that Sox10 positivity strongly correlates with fMaSC activity (Fig. 2I, Supp. Fig. 
3). Collectively, the data demonstrate that Sox10 expression labels cells in the fetal 
mammary rudiment that possess bipotent stem/progenitor features.
Notably, the organoid forming efficiency for fetal cells recovered with the Sox10-Venus and 
EpCAM markers represents a >3x improvement over the original CD24 and CD49f fMaSC 
marker strategy we previously employed. We isolated and RNA-sequenced E17 
Sox10+;EpCAM+ fMaSCs and their surrounding fetal stromal cells (Supp. Table 1). In 
parallel, we RNA-sequenced E17 fMaSCs isolated by sorting for CD24hi;CD49f+ cells to 
assess the purification afforded by Sox10 and EpCAM. Comparison of these transcriptome 
profiles revealed that numerous stromal-associated genes were removed from the E17 
fMaSC profile by using Sox10 expression to purify fMaSCs (Fig. 2J). Taken together, our 
data show that using Sox10 as a marker produces an fMaSC population significantly purer 
than obtained previously.
Sox10 labels cells with stem/progenitor features in adult mammary tissues
We next analyzed Sox10 expression in the adult mammary gland. Immunofluorescence 
against positional markers such as EpCAM (high in luminal cells, low in basal cells) 
indicated that Sox10 expression was more restricted in the adult gland compared to the fetal 
mammary rudiment (Fig. 3A). To quantify the expression of Sox10 by cell type, Sox10-
H2BVenus and Sox10flox-GFP adult glands were FACS sorted into basal and luminal 
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fractions using EpCAM/CD49f and the percentage of Sox10+ cells in each fraction was then 
determined. These analyses revealed that nearly all basal cells express Sox10, while ~50% 
of luminal cells express Sox10 (Fig. 3B, Supp. Fig. 4).
Mammary stem/progenitor cell assays were performed on these Sox10+ basal and luminal 
cells to better understand their function in the gland. Sox10+ and Sox10neg luminal cells 
were isolated by FACS and plated into 3-D culture conditions. While Sox10+ luminal cells 
demonstrated sphere forming potential with luminal characteristics (18.0 +/− 2.1%), 
Sox10neg luminal cells did not form spheres (0.3 +/− 0.3%, Fig. 3C, Supp. Fig. 4). This 
suggests that Sox10+ luminal cells demarcate the colony-forming luminal progenitor cells in 
the luminal fraction of the mammary gland. Consistent with this, Sox10+ cells do not 
express progesterone receptor, a mature luminal cell marker, which is instead exclusively 
expressed in Sox10neg luminal cells (Fig. 3D). In the basal cell fraction, both Sox10+ and 
less common Sox10neg basal cells were transplanted into cleared fat pads to determine 
MaSC function in an in vivo context. Sox10+ basal cells exhibited robust repopulation 
potential, whereas no successful transplantation was observed with Sox10neg basal cells 
(Fig. 3E, F). Sox10+ luminal cells also failed to exhibit successful transplantation, further 
indicating that these are lineage restricted progenitor cells.
These data indicate that populations with known mammary stem/progenitor cell properties
—fMaSCs in the fetal rudiment, repopulating MaSCs in the adult basal fraction, and luminal 
progenitors in the luminal layer of the mammary gland, all appear to express Sox10.
Sox10 labels cultured mammary cells with stem/progenitor characteristics in vitro
The correlation of Sox10 expression with mammary stem/progenitor populations in vivo led 
us to next investigate if Sox10 also labels cells with these properties in organoids grown 
from fMaSCs in vitro. To address this, Sox10-H2BVenus fMaSCs were grown into bi-
lineage organoids in 3-D culture conditions. Intriguingly, these structures exhibited mosaic 
Sox10 expression in which Sox10+ and Sox10neg cells were clearly evident (Fig. 4A). To 
determine if these cells differ in stem/progenitor functionality, these populations were 
isolated and replated into identical organoid-forming conditions to generate secondary 
organoids in a classic surrogate assay of self-renewal for stem cells. Notably, Sox10+ cells 
from primary organoids had significantly greater potential to form secondary organoids than 
Sox10neg cells (Fig. 4B). Further, the secondary structures from Sox10+ cells were larger 
and yielded clear bi-lineage differentiation with both luminal and basal cell types present 
(Fig. 4C). The rare secondary outgrowths derived from Sox10neg cells were by contrast 
smaller and appeared to lack the bi-lineage structure observed in primary and Sox10+ 
secondary organoids (Fig. 4C). These secondary organoids appeared to show more luminal-
restricted Sox10 expression compared to primary organoids, which may reflect the 
restriction in stem/progenitor competence that occurs in this differentiation medium, and 
may mimic native mammary cell hierarchy. These data indicate that in addition to mammary 
cells in vivo, Sox10 labels populations with enhanced stem/progenitor functions in cultured 
mammary organoids in vitro.
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Sox10 functionally contributes to stem/progenitor activity in mammary cells
We next determined if Sox10 actively contributes to fMaSC function by performing stem/
progenitor assays on cells in which Sox10 expression was ablated by deletion. We infected 
Sox10flox/flox and Sox10wild-type fMaSCs with Cre-expressing lentivirus to delete Sox10 
from the Sox10flox cells. While Cre-infected Sox10wild-type fMaSCs generated typical 
organoids with luminal and basal architecture resembling the mammary gland, the Cre-
infected Sox10flox/flox fMaSCs generated fewer organoids, and the structures that did form 
were typically smaller and failed to develop the morphological features of multi-lineage 
organoids (Fig. 4D, Supp. Fig. 5).
We also performed transplantation assays with Cre-infected Sox10flox/flox fMaSCs or 
Sox10flox/flox adult basal cells to determine if cells were capable of generating full 
outgrowths following Sox10 deletion. No full outgrowths following transplantation were 
observed in the Sox10null MaSCs, whereas equivalent numbers of control cells exhibited 
successful transplantation (Fig. 4E, Supp. Fig. 5). Together these data indicate that Sox10 is 
required for full stem/progenitor cell functionality.
To determine if overexpression of Sox10 can increase stem/progenitor function in mammary 
cells, the Tet-on system was used to drive expression of human Sox10 in fMaSCs. fMaSCs 
isolated from a mouse strain that ubiquitously expresses the m2rtTA reverse tetracycline 
transactivator were infected with either LV-TRE-hSox10-2A-NLSVenus (doxycyline (dox) 
induces expression of Sox10 and Venus) or LV-TRE-NLSVenus (dox induces expression 
only of Venus) and allowed to form primary organoids. No apparent increase in primary 
organoid formation was observed with Sox10-overexpression (Sox10OE). These primary 
organoids were then dissociated to single cells, replated into identical culture conditions, and 
scored for their ability to generate secondary organoids as a metric for increased persistence 
of stem/progenitor function. While fMaSCs that did not overexpress Sox10 showed low 
ability to form secondary organoids in differentiation medium (Fig. 5A), Sox10OE fMaSCs 
now demonstrated robust secondary organoid formation (Fig. 5A, B). These data indicate 
that ectopic expression of Sox10 is able to increase or sustain stem/progenitor competence in 
cultured fetal mammary cells.
Ectopic Sox10 expression drives an EMT-like response in fMaSC-derived organoids
While measuring the stem/progenitor function of Sox10OE cells, we discovered that primary 
organoids with Sox10OE cells demonstrated a novel morphology in which the primary 
organoid was surrounded by individual cells (Fig. 5C). Video microscopy showed that the 
satellite cells originate from the delamination and extrusion of Sox10OE cells from the 
primary organoid (Fig. 5D, Videos). We found that Sox10OE (Venus+) cells no longer 
expressed keratin markers, suggesting that the mobility of the cells might result from 
Sox10OE-induced EMT (Fig. 5E, Supp. Fig. 6). Sox10OE cells also presented with additional 
EMT markers, including downregulated expression of E-cadherin and upregulated 
expression of vimentin (Fig. 5F, Supp. Fig. 6). No such changes were observed in organoids 
not exposed to Dox. These data demonstrate that Sox10 can directly mediate an EMT-like 
response when forcibly expressed at high levels in fMaSC-derived organoids.
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We next determined if the EMT state could be reversed in Sox10OE mammary cells and if 
they retained or could regain bipotential stem/progenitor function. Sox10OE mammary cells 
were isolated from primary organoid cultures and replated into 3-D culture conditions with 
or without dox. The Sox10OE mammary cells that were plated into dox, and thus maintained 
high Sox10 expression, often persisted as single cells and did not organize into secondary 
organoids (Fig. 6A). However, when these same cells were plated into dox-free media, and 
Sox10 levels were reduced to baseline (Supp. Fig. 7), the cells now favored the formation of 
bi-lineage secondary organoids (Fig. 6A).
The same phenomenon was observed when Sox10OE organoids that had undergone EMT 
and cell delamination were subjected to a protocol that removed dox from the media and 
lowered Sox10 expression to basal levels. While organoids continuously exposed to dox and 
high Sox10 levels showed mostly persistent single cell satellite structures, the satellite cells 
in the dox-withdrawn organoids now initiated the formation of localized secondary 
organoids (Fig. 6B). These secondary organoids exhibited the same bi-lineage features of 
primary fMaSC organoids, indicating that these single Sox10OE cells have the potential to 
produce both luminal- and basal-like cells (Fig. 6C). Notably, this robust secondary 
organoid formation occurred in the same strong differentiation media in which cells with 
retained stem/progenitor qualities are rare (Fig. 4B), indicating the downstream effects of 
Sox10 serve to counterbalance these pro-differentiation factors.
These data reveal that at high levels of expression, Sox10 induces a mesenchymal transition 
that enables cell migration away from primary organoids. These cells are then capable of 
undergoing a mesenchymal-epithelial transition (MET) that mediates the formation of 
secondary organoids, which appears to be favored when Sox10 expression levels are 
reduced.
FGF signaling is required for Sox10-induced cell motility
We next attempted to identify mechanisms through which Sox10 evokes stem/progenitor 
and EMT/motility functions in mammary cells. The feedback loop between Sox 
transcription factors and FGF signaling that appears to involve Sox10 and FGF10 in 
mammary cells (Fig. 1) suggests that these Sox10-mediated cell functions could involve 
FGF signaling. To test this, fMaSCs were manipulated to overexpress Sox10 as before, but 
this time in the presence of FGFRi. As expected, fMaSCs that were given vehicle formed 
primary organoids and the overexpression of Sox10 elicited an EMT-like delamination of 
cells (Fig. 7A). However, this cell delamination was significantly attenuated in organoids 
that were exposed to the FGFRi, as indicated by the absence of satellite cells surrounding 
the primary organoid (Fig. 7A, B). Sox10OE organoids that were grown in media without 
FGF also failed to extrude satellite cells, confirming that it is inhibition of FGF signaling by 
the FGFRi that mediates this effect (Fig. 7C). These data suggest that the potentiation of 
FGF signaling can be one effector of Sox10 that mediates cell delamination, and that a pan-
FGFRi blocks Sox10-induced motility in fMaSC-derived mammary organoids.
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Transcriptome analyses of Sox10OE cells indicate potential mediators of stem and EMT 
functions
To more comprehensively profile the state changes elicited by Sox10 and to identify other 
potential direct or indirect targets of Sox10 that could mediate the stem/progenitor and 
EMT-like functions of Sox10, we performed transcriptome profiling of Sox10OE cells 
through RNA sequencing (Supp. Table 2). In parallel, we also isolated and RNA-sequenced 
control organoid cells that did not overexpress Sox10 for comparison. To assess the quality 
of the sequencing data, we determined if previously described targets of Sox10 were 
upregulated in response to Sox10 overexpression. Published targets such as Mitf, Mia, and 
ErbB3 all showed elevated expression in Sox10OE cells (Bondurand et al., 2000; Graf et al., 
2014; Prasad et al., 2011) (Fig. 7D). We also analyzed targets of FGF signaling, given our 
data linking Sox10 and FGF signaling. Among the targets induced by Sox10, we found that 
the FGF positive signaling regulator Etv5 was upregulated, while the FGF negative regulator 
Dusp6 was downregulated (Fig. 7D). This is consistent with the positive FGF-Sox10 loop 
indicated by our data, in which FGF acts to induce Sox10, while activated Sox10 then 
reinforces FGF signaling. These data validate that the differential expression of molecules 
between Sox10OE and control cells can be used to identify targets of Sox10 or signaling 
network changes initiated by Sox10.
We next identified genes that were significantly differentially expressed in response to 
Sox10OE. Gene ontology analysis with these gene lists indicated significant reprogramming 
of cellular function that is consistent with the observed phenotypic changes in Sox10OE cells 
(Fig. 7D, Supp. Table 2). For example, Sox10OE cells delaminate from the primary organoid 
where they tend to remain quiescent, and indeed this analysis finds genes associated with 
migration are upregulated with Sox10OE, while genes associated with proliferation and 
adhesion are downregulated with Sox10OE. Similarly, Sox10OE cells in organoids lose 
differentiation marker expression and gain stem/progenitor function during this process, and 
indeed genes associated with differentiation are downregulated with Sox10OE. These 
transcription data thus provide a hypothesis generating resource to determine how Sox10 
elicits important state changes in normal or transformed mammary cells.
Notably, ErbB2 and the estrogen and progesterone hormone receptors all showed reduced 
expression levels following Sox10 overexpression. Sox10 is preferentially expressed in 
triple negative breast cancers that lack these three receptors (Fig. 1F). These data suggest 
that Sox10 may be one mechanism of functionally specifying this triple negative state.
Discussion
Our studies have used diverse strategies to reveal important roles for Sox10 in stem and 
progenitor functions within mammary cells. This is first indicated by the significant 
correlation between Sox10 expression and two aggressive subtypes of breast cancer that 
have previously been described as stem-like (basal-like) or EMT-like (claudin-low). We 
then present data that Sox10 consistently labels cells with stem/progenitor qualities in 
multiple contexts that include fetal, adult, and 3-D cultured mammary tissues. Sox10 may be 
a cell state regulatory node in mammary cells, as deleting Sox10 decreased stem/progenitor 
functions, while its ectopic activation both expanded stem/progenitor activity and induced 
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EMT. This suggests that relative expression levels of Sox10 can mediate either stem-like or 
EMT-like responses depending on context.
The link between Sox10 and both stem- and EMT-like cell functions is reminiscent of the 
published links between CSCs and EMT (Oskarsson et al., 2014). Importantly, it has been 
unclear to what extent CSCs are stem-like, given that their mesenchymal properties and 
transcriptome profiles often do not resemble those of bone fide stem cells. The enhanced 
motility of mesenchymalized cells may endow them with greater capacity to aggregate and 
form polyclonal “tumorspheres” in suspension cultures, or to invade and form tumors more 
efficiently in xenograft assays. These properties are clearly independent of stemness 
measured by transcription profiling, and should not be used as surrogates for stem cell 
function. These concerns have led to the rebranding of CSCs as “tumor-” or “xenograft-
initiating cells”, which suggests the distinction between the stem-like cells in tumors 
identified transcriptionally, and the more EMT-like CSCs.
The data described here present clear evidence that the stem cell and mesenchymal states are 
related and can be interconverted in stem-like cells. We find that a single factor, Sox10, is 
able to contribute to cells entering each of these two states, and critically we show that it 
does so independently of the other state. Sox10+ cells that have not undergone EMT show 
increased levels of stemness in multiple contexts, while EMT occurs independent of stem 
cell activity. The separation of these states removes the aforementioned concerns about 
conflating stemness with properties of mesenchymal cells, and demonstrates that a single 
molecule such as Sox10 can link these two distinct states. Importantly, this affirms the link 
between stem-like and mesenchymal states, and defines a molecular mechanism by which 
these state conversions can take place.
These data also yield predictions about how mammary cells acquire stem cell-like properties 
in normal and cancerous states, and how these mechanisms may contribute to metastatic 
disease. The capacity of Sox10 to promote both stem-like and EMT-like behaviors, suggests 
that Sox10 could be a factor that mediates these two functions that are hypothesized to be 
directly responsible for tumor initiation and progression. Most notably, we have modeled the 
sequential stages of metastatic behavior using only Sox10 in 3-D mammary cell culture, as 
we find that: 1) Sox10+ cells preferably form primary organoids, 2) Sox10OE activates EMT 
to elicit delamination and migration of cells away from the primary organoid, and 3) 
reduction of Sox10 levels in these cells reverses the EMT and initiates the establishment of 
separate organoids at secondary sites. It is easy to visualize how this could similarly play out 
in Sox10+ tumors, in which microenvironmental or genomic changes could induce 
fluctuations in Sox10 expression levels that cycle cells through these stem-like and EMT 
states to mediate metastasis.
Our findings also have implications for how stem/progenitor cell states may be specified in 
mammary cells. As discussed in the introduction, the balanced activation of specific lineage 
determining factors is a mechanism capable of mediating stem-like functions in cells. This 
model fits with observations of Sox family transcription factors, where Sox molecules have 
antagonistic relationships with other factors at cell fate decision points. By applying this 
model to Sox10 and mammary cells, our data indicate that Sox10 may specify the basal 
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lineage in mammary cells. This is apparent in the expression data, where Sox10 
preferentially labels the basal cell fraction in the adult mammary gland, and the functional 
data, as Sox10OE can elicit EMT in mammary cells, and basal cells can be considered 
“partial EMT” based on their morphology. Furthermore, this model predicts that Sox10 
should promote stem-like qualities when in balance with other factors. This is supported by 
our data linking Sox10 expression and function to stem-like properties, and our data 
demonstrating that lower levels of Sox10 expression increase efficiency of bi-lineage sphere 
formation and self-renewal. These data thus support a model in which cell fate decisions and 
stemness in mammary cells are regulated by a balance of lineage specifiers, of which Sox10 
is one critical player that favors a basal lineage. However, there are pieces of our data that 
do not neatly fit this model, such as that Sox10neg cells produce mostly basal-like organoids 
and Sox10OE elicits cells that appear less differentiated. This suggests that a function of 
Sox10 may be to provide cell state plasticity, instead of, or in addition to, a role in lineage 
specification.
As described in the introduction, there is not a consensus on the localization and frequency 
for MaSCs. Our data and the balanced lineage specifier model suggest that a significant 
reservoir of Sox10-expressing poised basal cells exists, and that these cells could adopt 
activated stem/progenitor cell properties by the acquisition of antagonistic factors that bring 
Sox10 levels into an equilibrium that favors a stem cell state. This is consistent with work 
that indicates the majority of single basal cells have the potential to generate full mammary 
glands (Prater et al., 2014). Evaluating this model will require a better understanding of how 
Sox10 works in concert with other, presumably pro-luminal factors, such as Elf5, Gata3, and 
Notch signaling, among others. Similarly, it will be key to evaluate the relationship of Sox10 
with basal lineage regulators such as p63 and Slug, and the stem-cell marker Lgr5 (Oakes et 
al., 2014).
Finally, two of our most striking results are that the use of an FGFR inhibitor profoundly 
affects the expression of Sox10 and the delamination phenotype induced through Sox10OE. 
Notably, the deletion of FGFR1 and FGFR2 results in the loss of the transplantation 
competent population of mammary stem cells and compromises ductal remodeling, which 
mirror the roles for Sox10 in stem cell competence and cell motility shown here (Pond et al., 
2013). Extrinsic signaling mechanisms in the stem cell niche that regulate the frequency and 
output of stem cells are potential targets for cancer prevention or treatment. Thus it will be 
key to determine if blocking FGF signaling also antagonizes the expression or downstream 
effects of Sox10 (or other Sox family transcription factors) in vivo in normal mammary 
tissue or tumors. Together these data imply a central role for FGF signaling and Sox10 in 




Single cell preparations of fetal mammary cells were obtained by pooling freshly dissected 
fetal mammary rudiments from euthanized embryos into dissociation media: Epicult-B 
Basal medium (Stem Cell Technologies) supplemented with 5% FBS, pen/strep, fungizone, 
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hydrocortisone, collagenase and hyaluronidase. Rudiments were then dissociated to single 
cells by sequentially incubating them in dissociation medium for 1.5 hours at 37°C with 
gentle agitation, exposing them to ammonium chloride for 4 minutes on ice to remove 
erthyrocytes, and triturating them with dispase and DNase. Final suspensions were passed 
through a 40 um filter to remove aggregated cells, and stored in Hank’s Balanced Salt 
Solution with 2% FBS for flow cytometry. Single cell preparations of adult mammary cells 
were prepared by dissecting out and mincing the #4 mammary glands from 6–12 week old 
virgin female mice. Glands were then dissociated by agitating them for 3–6 hours at 37°C in 
the same dissociation media. Cells were further processed as with the fetal cells, except that 
trypsin and accutase (Life Technologies) were also utilized prior to dispase treatment to 
facilitate disaggregation. Final suspensions were passed through a 40 um filter to remove 
cell clusters, and stored in Hank’s Balanced Salt Solution with 2% FBS for flow cytometry.
Immunostaining and confocal analyses
Mammary tissues were immunostained through direct or indirect immunofluorescence. 
Confocal microscopy was performed with equipment from the Waitt Advanced 
Biophotonics Center at the Salk Institute, including Zeiss 780 inverted laser scanning 
confocal microscopes. Details of tissue preparation and staining protocol are included in the 
Supplement.
3-D organoid culture
To generate organoids, single mammary cells were plated at 50–650 cells per well in 96-
well ultra low-adhesion plates (Costar) with Matrigel. Cells were plated in either restricted 
serum-free media (Epicult-B media with B-supplement (Stem Cell Technologies) containing 
heparin and pen/strep, and defined growth factors such as EGF, FGF2, and/or FGF10), or in 
serum-based MCF10A media (DMEM/F12 with 5% horse serum, hydrocortisone, cholera 
toxin, insulin, and ciproflaxin, supplemented with B27 supplement and EGF). Description of 
the plating protocol and analysis of these cells is in the Supplement.
4-D Organoid culture and imaging
m2rtTA fMaSCs were infected with LV-TRE-hSox10-2A-NLSVenus and plated onto glass 
bottom 35 mm dishes with a Matrigel bed in restricted serum-free media. After 72 hours, 
organoids were given fresh media and dox to induce Sox10/Venus expression. 8–24 hours 
later, cells were imaged at 10 minute intervals with a Zeiss CSU Spinning Disk Confocal 
Microscope in a climate-controlled environment of 5% CO2 and 37° C. Images were 
assembled into movies using Imaris imaging software.
RNA sequencing and Bioinformatic analyses
RNA isolation, sequencing, and analysis are described in detail in the Supplement. The 
RNA-sequencing data are available at the gene expression omnibus under accession GEO: 
GSE71300.
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A two-tailed student’s t-test was used to quantify significance. P values were represented as 
follows: * - p<0.05, ** - p<.005, *** - p<.0001. The error bar in all figures is the standard 
deviation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A) Log2 microarray expression values for Sox10 and FGF signaling molecules in E18 
fMaSCs and fStroma. B) E18 fMaSCs grown in 3-D culture conditions for 5–7 days with the 
indicated media. Scale bar 150 um. C) Sox10 mRNA levels expression levels in fMaSC-
derived organoids grown with FGFRi for 7 days. D) FACS-based quantification of Venus+ 
cells in 7-day old FGFRi-treated organoids grown from Sox10-H2BVenus fMaSCs or adult 
mammary luminal progenitors. In C–E, the Y-axis represents the # of Venus+ cells as a % of 
the total # of cells in the primary organoids, normalized to the vehicle. E) FACS-based 
quantification of Venus+ cells in 8-day old organoids grown from E18 Sox10-H2BVenus 
fMaSCs in defined growth factors. X-axis is Venus fluorescence, # in box is % gated 
Sox10+ cells. F) Whisker plots for Sox10 expression from the Metabric and UNC885 breast 
tumor databases across multiple subtypes. Each dot is a Sox10 expression value from a 
particular tumor.
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A) Wholemount view of the 1–3 mammary rudiment pairs in an E18 Sox10-H2BVenus 
embryo. B–C) Venus fluorescence in E16 & E18 Sox10-H2BVenus mammary rudiments 
wholemounts. D) Wholemount mammary rudiment from E18 Sox10-H2BVenus embryo 
immunostained with luminal (K8) and basal (K14) markers. E) FACS of E18 Sox10-
H2BVenus fetal mammary cells (pre-gated for EpCAM+ cells). F) Keratin immunostain of 
single E18 Sox10flox-GFP EpCAM+ fetal mammary cells. G) Efficiency of organoid 
formation from E18 Sox10-H2BVenus female mammary rudiments in two different media. 
Y-axis is # of organoids per 100 cells plated. H) A bi-lineage organoid derived from 
fMaSCs. I) A reconstituted mammary gland following transplantation of Sox10+ fetal cells 
visualized by Sox10-H2BVenus reporter. J) Sox10-H2BVenus-derived fMaSCs (columns 1 
and 2), CD24/CD49f-derived fMaSCs (columns 3 and 4), and fStroma (columns 5–7) were 
RNA-sequenced and clustered (SAM: FDR<0.01%) using previously indicated differentially 
expressed genes between fMaSC (pink) and fStroma (green).
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A) Immunostain for EpCAM in an adult Sox10-H2BVenus mammary gland. B) FACS of 
Venus fluorescence (X-axis) in adult Sox10-H2BVenus luminal and basal populations (Y-
axis is EpCAM). Displayed are luminal cells that were pre-gated as 
EpCAMhi;CD49flow-med, and basal cells as EpCAMlow-med;CD49fhi. C) Venus(−) or 
Venus(+) luminal cells from an adult Sox10-H2BVenus mammary gland cultured in 3-D for 
6 days. Scale bar 65 um. D) Wholemount immunofluorescence for K8 and progesterone 
receptor (Pgr) from adult Sox10-H2BVenus mammary glands; right image lacks Pgr for 
easier visualization. E) Transplantation take rates for Venus(−) and Venus(+) basal cells 
from an adult Sox10-H2BVenus mammary gland. F) A reconstituted mammary gland 
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following transplantation of Sox10+ adult basal cells visualized by the Sox10-H2BVenus 
reporter.
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A) Organoids from Sox10-H2BVenus fMaSCs contain Venus(+) and Venus(−) cells. B–C) 
Efficiency of secondary organoid formation for Venus(+) and Venus(−) cells taken from 
primary Sox10-H2BVenus fMaSC organoids grown in SFM. Y-axis is # of secondary 
organoids per 100 cells plated. D) Representative organoid formation following 3-D culture 
of Cre-infected Sox10wild-type or Sox10flox/flox fMaSCs. E) Carmine staining of transplanted 
Cre-infected Sox10wild-type or Sox10flox/flox fMaSCs into cleared fat pads. Transplants were 
considered takes if greater than half the fat pad was reconstituted; *marks a partial aborted 
outgrowth.
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A) Primary (1°) organoids from control (uninfected) or Sox10OE m2rtTA fMaSCs were 
dissociated and replated into 3-D culture to form secondary (2°) organoids. Shown is 2° 
organoid growth after 7 days. Scale bar 75 um. B) Quantification of 2° organoid forming 
potential for Sox10OE cells compared to uninfected or Venus-only infected cells. Y-axis is # 
of >50 um 2° organoids per 100 cells plated. C) Sox10OE fMaSCs present with satellite 
single cell structures surrounding the 1° organoid (*). Scale bar 40 um. D) Active 
delamination of cells from a Sox10OE organoid. E) Immunostains of control or Sox10OE 
fMaSC organoids demonstrate the loss of keratin expression (red or green) in Sox10OE cells 
(blue). Scale bar 50 um. F) Immunostains of Sox10OE fMaSC organoids reveal upregulation 
of vimentin and loss of E-cadherin in Sox10OE cells (blue).
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A) Sox10OE cells were isolated from 7-day old fMaSC-derived primary (1°) organoids and 
replated in 3-D culture +/− dox. Secondary outgrowths from these cells were immunostained 
for keratin markers after 7 days. B) Sox10OE satellite cells form secondary (2°) organoids 
surrounding the 1° organoid at greater efficiency if dox is removed from the media after 4 
days. Left/right are the same organoids over 10 days of culture. Scale bar 20 um. C) 
Sox10OE cells were allowed to form 1° organoids in 3-D culture for 7 days, then dox was 
washed out of the media to ease Sox10 expression. 3–4 days after washout, the delaminated 
satellite cells initiated 2° organoid formation (*) around the 1° organoid.
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A) Sox10OE organoids were grown in 3-D culture in the presence of vehicle or 1.0 uM 
FGFRi. 100 um scale bar. B) Fraction of Sox10OE organoids with extruded satellite cells 
after 6 days (Y-axis) in the presence of vehicle or 1.0 uM FGFRi. C) Sox10OE organoids 
were grown in 3-D culture in SFM with EGF alone or EGF, FGF2, and FGF10. Scale bar 40 
um. D) Gene ontology terms associated with significantly down- or up-regulated genes 
following Sox10OE (top) and example notable genes with altered expression by Sox10OE 
(bottom).
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